Search within these filings
View filings
Filing insights
- Data Charts
- Environmental, Social & Governance
- Financial Report Summaries
Export filings list
Export a CSV file of filings or unique filing companies (up to first 5,000 results).
Download list of filings Download list of companiesExternal links
Employees
Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
ClimateEnvironmentEnvironmentalMaterialsNatureOffsetPackagePackagingRaw MaterialsRegenerativeToxicWasteWindAccessBenefitsBlackCharitableCollective BargainingCommunityCultureCustomerCyberData PrivacyData SecurityDeathDisabilityDiversityEmployeeEngagementEthnicityGenderGeneral Data Protection RegulationHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesInjuryMinorityPay EquityPrivacyProduct SafetyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkilledSkillsSocialStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkforceActivistAssessmentAssuranceAttorneys GeneralAuditBonusBriberyChronicClass Action LawsuitClassifiedCommitmentCorporate GovernanceCorporate PurposeCorruptionDepartment ofEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityOverseeOversightPlaintiffProxy ContestPurposeR&DReputationReputationalResearch and DevelopmentResponsibilityResponsibleSpecial MeetingStrategyTargetsTaxTenureTransparencyVoting Rights
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years
DFAN14A
CYDY
CytoDyn Inc.
5 Nov 21
Additional proxy materials by non-management
11:30am
DFAN14A
CYDY
CytoDyn Inc.
26 Oct 21
Additional proxy materials by non-management
5:07pm
DFAN14A
CYDY
CytoDyn Inc.
19 Oct 21
Additional proxy materials by non-management
4:29pm
DFAN14A
CYDY
CytoDyn Inc.
14 Oct 21
Additional proxy materials by non-management
2:36pm
DFRN14A
CYDY
CytoDyn Inc.
6 Oct 21
Revised proxy by non-management
12:00am
DFAN14A
CYDY
CytoDyn Inc.
4 Oct 21
Additional proxy materials by non-management
9:36am
DFAN14A
CYDY
CytoDyn Inc.
30 Sep 21
Additional proxy materials by non-management
9:30am
DFAN14A
CYDY
CytoDyn Inc.
28 Sep 21
Additional proxy materials by non-management
10:01am
PREC14A
CYDY
CytoDyn Inc.
24 Sep 21
Preliminary proxy with contested solicitation
5:31pm
DFAN14A
CYDY
CytoDyn Inc.
24 Sep 21
Additional proxy materials by non-management
10:10am
DFAN14A
CYDY
CytoDyn Inc.
20 Sep 21
Additional proxy materials by non-management
2:24pm
DFAN14A
CYDY
CytoDyn Inc.
20 Sep 21
Additional proxy materials by non-management
9:30am
DFRN14A
CYDY
CytoDyn Inc.
17 Sep 21
Revised proxy by non-management
5:09pm
DFAN14A
CYDY
CytoDyn Inc.
17 Sep 21
Additional proxy materials by non-management
10:42am
DFAN14A
CYDY
CytoDyn Inc.
7 Sep 21
Additional proxy materials by non-management
1:48pm
DFAN14A
CYDY
CytoDyn Inc.
2 Sep 21
Additional proxy materials by non-management
1:52pm
DFAN14A
CYDY
CytoDyn Inc.
1 Sep 21
Additional proxy materials by non-management
9:00pm
DFAN14A
CYDY
CytoDyn Inc.
31 Aug 21
Additional proxy materials by non-management
4:59pm
DFAN14A
CYDY
CytoDyn Inc.
31 Aug 21
Additional proxy materials by non-management
4:55pm
DFAN14A
CYDY
CytoDyn Inc.
31 Aug 21
Additional proxy materials by non-management
2:08pm
DFAN14A
CYDY
CytoDyn Inc.
26 Aug 21
Additional proxy materials by non-management
5:17pm
DFAN14A
CYDY
CytoDyn Inc.
19 Aug 21
Additional proxy materials by non-management
4:49pm
DFAN14A
CYDY
CytoDyn Inc.
18 Aug 21
Additional proxy materials by non-management
5:16pm
DFAN14A
CYDY
CytoDyn Inc.
17 Aug 21
Additional proxy materials by non-management
12:00am
DFAN14A
CYDY
CytoDyn Inc.
13 Aug 21
Additional proxy materials by non-management
12:00am
DFAN14A
CYDY
CytoDyn Inc.
11 Aug 21
Additional proxy materials by non-management
9:09pm
DFAN14A
CYDY
CytoDyn Inc.
2 Aug 21
Additional proxy materials by non-management
5:18pm
PREC14A
CYDY
CytoDyn Inc.
20 Jul 21
Preliminary proxy with contested solicitation
5:05pm
DFAN14A
CYDY
CytoDyn Inc.
7 Jul 21
Additional proxy materials by non-management
4:16pm
DFAN14A
CYDY
CytoDyn Inc.
1 Jul 21
Additional proxy materials by non-management
5:27pm
Vote support at last AGM
CytoDyn Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on November 9, 2023. On November 9, 2023, the Inspector of Election issued its final report certifying the final voting results for the Annual Meeting, which were as follows:
1.Election of Directors.
The stockholders elected each of the Company’s director nominees to serve until the Company’s 2024 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.
2. Advisory vote on compensation of named executive officers.
The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.
3. Vote to amend the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares.
The stockholders approved an amendment to the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares.
1.Election of Directors.
| | | ||||
Nominee | | For | | Withheld | | Broker Non-Votes |
---|---|---|---|---|---|---|
Tanya Durkee Urbach | | 338,738,111 | | 36,531,676 | | 175,152,701 |
Stephen M. Simes | | 343,574,264 | | 31,695,523 | | 175,152,701 |
Ryan M. Dunlap | | 343,231,340 | | 32,038,447 | | 175,152,701 |
Lishomwa C. Ndhlovu, M.D., Ph.D. | | 342,240,886 | | 33,028,901 | | 175,152,701 |
Karen J. Brunke, Ph.D. | | 343,228,818 | | 32,040,969 | | 175,152,701 |
The stockholders elected each of the Company’s director nominees to serve until the Company’s 2024 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.
2. Advisory vote on compensation of named executive officers.
| | ||||
For | | Against | | Abstentions | Broker Non-Votes |
---|---|---|---|---|---|
297,528,035 | 63,576,401 | 14,165,351 | 175,152,701 |
The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.
3. Vote to amend the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares.
| | ||||
For | | Against | | Abstentions | |
504,658,717 | 42,575,745 | 3,188,026 | |
The stockholders approved an amendment to the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares.